Clinical Trials Logo

Unresectable Advanced Cancer clinical trials

View clinical trials related to Unresectable Advanced Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT02640365 Completed - Clinical trials for Unresectable Advanced Cancer

A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer

DOUBLIRI
Start date: November 18, 2015
Phase: Phase 1
Study type: Interventional

MM-398 (also known as PEP02) is nanoliposomal encapsulated irinotecan: the liposomal formulation is designed to extend plasma circulation and to increase accumulation in the tumor through the enhanced permeability and retention (EPR) effect. This study introduces a new concept of combining free and nanoliposomal drugs.